Rosetta Genomics Ltd. (NASDAQ: ROSG) develops and commercializes a broad range of microRNA-based and other high-value molecular diagnostics. The company’s integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Rosetta is currently working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools. For more information, visit the company’s website at www.rosettagenomics.com.